42160-40-7

Usage

Uses

Used in Pharmaceutical Industry:
4-(3,4-dichlorophenyl)butan-2-one is used as a key intermediate in the synthesis of various drugs and pharmaceuticals. Its unique structure allows it to be a valuable component in the development of new medications, contributing to the advancement of healthcare and treatment options.
Used in Organic Chemistry:
As an intermediate in organic chemistry, 4-(3,4-dichlorophenyl)butan-2-one is utilized in the production of a wide range of chemicals. Its reactivity and functional groups make it suitable for various chemical reactions, leading to the creation of new compounds with diverse applications.
Used in Chemical Production:
4-(3,4-dichlorophenyl)butan-2-one is also used as a reagent in the production of various other chemicals. Its presence in chemical processes can enhance the efficiency and effectiveness of these reactions, resulting in the creation of new chemical entities with potential uses in different industries.

Upstream product

• 102-47-6 3,4-Dichlorophenylmethyl chloride 
• 123-54-6 acetylacetone 
• 74546-02-4 4-(3,4-dichlorophenyl)-3-butene-2-one 
• 6287-38-3 3,4-dichlorobenzaldehyde 
• 598-32-3 2-hydroxy-3-butene 
• 20555-91-3 3,4-dichloroiodobenzene 
• 1429293-32-2 3-(3,4-dichlorophenyl)-N-methoxy-N-methylpropanamide 
• 75-16-1 methylmagnesium bromide 
• 25173-68-6 3(3,4-dichlorophenyl)propanoic acid 

Downstream Products

• 93467-64-2 4-(3,4-dichlorophenyl)butan-2-amine 
• 1429188-09-9 (S)-N-((S)-4-(3,4-dichlorophenyl)butan-2-yl)-2-methylpropane-2-sulfinamide 
• 1425370-65-5 (S)-N-((R)-4-(3,4-dichlorophenyl)butan-2-yl)-2-methylpropane-2-sulfinamide 
• 1425093-26-0 C₁₄H₂₁Cl₂NOS 
• 1425092-18-7 C₁₉H₁₇Cl₂F₆N 
• 1425093-32-8 C₁₅H₂₃Cl₂NOS 
• 1425092-23-4 4-trifluoromethylbenzaldehyde 
• 1425093-35-1 C₁₈H₁₃Cl₄NO₂ 
• 1425092-24-5 C₁₈H₁₇Cl₄N 
• 1425092-25-6 C₁₉H₁₈Cl₂F₃N 
• 1425093-25-9 C₁₄H₁₉Cl₂NOS 

Relevant academic research and scientific papers

PK/PD Disconnect Observed with a Reversible Endothelial Lipase Inhibitor

Screening of a small set of nonselective lipase inhibitors against endothelial lipase (EL) identified a potent and reversible inhibitor, N-(3-(3,4-dichlorophenyl)propyl)-3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (5; EL IC50 = 6

COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE

This invention relates to novel diarylamino compounds that bind to the sigma-2 receptor, to pharmaceutical compositions comprising such compounds, and to methods for inhibiting or restoring synapse loss in neuronal cells, modulating a membrane trafficking

COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE

This invention relates to novel diarylamino compounds that bind to the sigma-2 receptor, to pharmaceutical compositions comprising such compounds, and to methods for inhibiting or restoring synapse loss in neuronal cells, modulating a membrane trafficking

QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE

The present invention provides compounds of Formula (I): (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.

PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments. The disclosure also provi

PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS

The present invention provides compounds of Formula (I) or Formula (III): [INSERT CHEMICAL STRUCTURE HERE] (I) [INSERT CHEMICAL STRUCTURE HERE] (III) as defined in the specification and compositions comprising any of such novel compounds. These compounds

AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIGANDS

The present invention relates to the CCR3 receptor ligands of the general formula (I), within them favourably to antagonists and to the salts, solvates and isomers thereof, to the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I) and their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers and to the new intermediates of the general formula (III).